2 transcripts
RYTM
Earnings call transcript
NASDAQ
2024 Q1
7 May 24
be challenging in general, but particularly when it comes to a chronic daily injectable therapy.
Overall, the specific reasons for discontinuation remained
RYTM
Earnings call transcript
NASDAQ
2023 Q4
22 Feb 24
we complete our chronic toxicity studies, which are required to support longer dosing and those chronic toxicity studies are ongoing and running
- Prev
- 1
- Next